16.06.2007: Press release: siRNAsense chooses Polyplus-transfection's delivery system 
siRNAsense today announces that the company has chosen to use Polyplus-transfection’s “in vivo-jetPEI” delivery system for the systemic delivery of their drug candidate “siRNA targeting Tissue Factor” for treatment of melanoma metastasis. siRNAsense selected Polyplus´ delivery system after experimental validation of several potential delivery systems. Read more.

12.06.2007: siRNAsense has received support from the Norwegian Research Council for development of the Tissue Factor project, targeting metastatic melanoma. 
As one of five companies, siRNAsense received support from the Norwegian Research Council's FUGE / BIP program for the development of the Tissue Factor Project targeting metastatic melanoma in 2008 and 2009. We see this as an aknowledgement of the quality of this project, and see this as a very important factor in the development of the drug candidate towards clinical studies.

22.11.2007: siRNAsense a member of Oslo Cancer Cluster

siRNAsense AS announces that it has been accepted as a member of Oslo Cancer Cluster (OCC), a Norwegian Centre of Expertise (NCE). The purpose of Oslo Cancer Cluster is to give patients access to better cancer diagnostics and therapies. OCC wants to be instrumental in moving scientific progress from the world-class research performed inside the cluster companies and supporting university hospitals to the world market.
Oslo Cancer Cluster aims to become Europe's leading comprehensive cancer cluster along the lines of the highly successful US model from MD Anderson Cancer Center and Memorial- Sloan Kettering Cancer Center.
OCC web pages:www.oslocancercluster.no

25.06.2007: Completed capital increase

siRNAsense AS announces today a completed capital increase of NOK 4.1 million. This will allow the company to speed up the development of the lead drug candidate and move towards filing an IND, and also to secure IP on other pipeline drugs. The next round of financing is expected to take place in June 2008. Prospect and information: sirnasense[at]sirnasense.com.

Meetings, Exhibitions, and Seminars - Come and See Us!

During the next few months, you can visit us at any of the events listed below.

• BIO2008, San Diego, June 17.-20. Program and info

Passed events 2007:

• Biotek-raketten, a part of Gründerdagen, October 18th, 2007. siRNAsense presented its current status in drug development to a panel of biotechnology focused investors, together with 7 other selected young biotech companies.
• The Oslo RNAi Conference 2007 in May. Themes will be the current development of RNAi, technology status and IP protection of your inventions.
  Speakers:
  (Presentations are available for downloading upon request)
  1. Hanne Mette D. Kristensen, CEO, siRNAsense AS
  2. Mohammed Amarzguioui, Ph.D., siRNAsense AS/ The Biotechnology Centre of Oslo 
  3. Mark Behlke, VP, Molecular Genetics, Integrated DNA Technologies
  4. Roland Kreutzer, Managing Director, Alnylam Europe AG
  5. Hans Boström, Director, Scientific Liaison, Scandinavia and the Baltic Countries, Merck, Sharp & Dome
  6. Anders Høgset, CEO and Research Director, PCI Biotech AS
  7. Kari Simonsen, Onsagers AS
  8. Mouldy Sioud, Group Leader, DEA Pharm, Ph.D., Rikshospitalet-Radiumhospitalet HF
  9. Torgeir Holen, Ph.D., CMBN, Rikshospitalet-Radiumhospitalet HF
  10. Pål Sætrom, Ph.D., NTNU
• Biosquare, Lyon, March 2007.
  http://www.biosquare.com/
• Keystone symposium:
  RNAi for Target Validation and as a Therapeutic, Jan 28 - Feb 2, Keystone, Colorado
  http://www.keystonesymposia.org/Meetings/ViewMeetings.cfm?MeetingID=824
  
  
  
  
  siRNAsense is dedicated to superior customer service; if you have any questions feel free to contact us.